NEW YORK, Jan. 26, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX) today announced the commercial launch of BRIUMVI™ (ublituximab-xiiy), for the treatment of relapsing forms of multiple ...
BARCELONA, Spain — Annual dosing of rituximab for relapsing-remitting multiple sclerosis (RRMS) was noninferior to the typical dosing schedule of once every 6 months, which could offer a more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results